Perioperative management of dual anti-platelet therapy

Tyler D. Webster, Prashant Vaishnava, Kim A. Eagle

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Dual anti-platelet therapy denotes a regimen of aspirin plus a P2Y12 receptor inhibitor, clopidogrel, prasugrel, or ticagrelor. Such therapy is a cornerstone of medical management following acute coronary syndromes and is imperative following percutaneous coronary interventions. While there is uncertainty about the optimal duration of dual antiplatelet therapy following percutaneous coronary intervention, the new 2016 American College of Cardiology/American Heart Association Guidelines suggest that for patients with stable ischemic heart disease at least six months of such therapy following a drug eluting stent and one month following a bare metal stent should be implemented. In patients with acute coronary syndrome including non-ST elevation and ST elevation myocardial infarction it is recommended to extend dual antiplatelet therapy treatment to one year in both drug eluting stent and bare metal stent groups. There may be latitude for earlier discontinuation in appropriately selected patients; extended dual antiplatelet therapy beyond one year may be beneficial in others. Herein, we describe current guidelines and evidence supporting if and when dual antiplatelet therapy should be interrupted for surgery for patients who have undergone percutaneous coronary intervention.

Original languageEnglish
Pages (from-to)237-241
Number of pages5
JournalHospital Practice
Issue number5
StatePublished - 1 Dec 2016
Externally publishedYes


  • DAPT
  • Dual-Antiplatelet Therapy
  • PCI
  • aspirin
  • bridging
  • clopidogrel
  • discontinuation
  • perioperative
  • surgery


Dive into the research topics of 'Perioperative management of dual anti-platelet therapy'. Together they form a unique fingerprint.

Cite this